Role of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders.

TitleRole of neurotrophic factor alterations in the neurodegenerative process in HIV associated neurocognitive disorders.
Publication TypeJournal Article
Year of Publication2014
AuthorsFields, J, Dumaop, W, Langford, TD, Rockenstein, E, Masliah, E
JournalJ Neuroimmune Pharmacol
Volume9
Issue2
Pagination102-16
Date Published2014 Mar
ISSN1557-1904
KeywordsAIDS Dementia Complex, Animals, Cognition Disorders, External, Humans, Nerve Degeneration, Nerve Growth Factors
Abstract

Migration of HIV infected cells into the CNS is associated with a spectrum of neurological disorders, ranging from milder forms of HIV-associated neurocognitive disorders (HAND) to HIV-associated dementia (HAD). These neuro-psychiatric syndromes are related to the neurodegenerative pathology triggered by the release of HIV proteins and cytokine/chemokines from monocytes/macrophages into the CNS -a condition known as HIV encephalitis (HIVE). As a result of more effective combined anti-retroviral therapy patients with HIV are living longer and thus the frequency of HAND has increased considerably, resulting in an overlap between the neurodegenerative pathology associated with HIV and that related to aging. In fact, HIV infection is believed to hasten the aging process. The mechanisms through which HIV and aging lead to neurodegeneration include: abnormal calcium flux, excitotoxicity, signaling abnormalities, oxidative stress and autophagy defects. Moreover, recent studies have shown that defects in the processing and transport of neurotrophic factors such as fibroblast growth factors (FGFs), neural growth factor (NGF) and brain-derived growth factor (BDNF) might also play a role. Recent evidence implicates alterations in neurotrophins in the pathogenesis of neurodegeneration associated with HAND in the context of aging. Here, we report FGF overexpression curtails gp120-induced neurotoxicity in a double transgenic mouse model. Furthermore, our data show disparities in brain neurotrophic factor levels may be exacerbated in HIV patients over 50 years of age. In this review, we discuss the most recent findings on neurotrophins and HAND in the context of developing new therapies to combat HIV infection in the aging population.

DOI10.1007/s11481-013-9520-2
Alternate JournalJ Neuroimmune Pharmacol
PubMed ID24510686
PubMed Central IDPMC3973421
Grant ListR01 AG043384 / AG / NIA NIH HHS / United States
U24 MH100928 / MH / NIMH NIH HHS / United States
P30 NS076411 / NS / NINDS NIH HHS / United States
R01 MH062962 / MH / NIMH NIH HHS / United States
R37 AG018440 / AG / NIA NIH HHS / United States
P30 MH062512 / MH / NIMH NIH HHS / United States
P01 AG022074 / AG / NIA NIH HHS / United States